Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
Browsing: clinical trial
At ECTRIMS, we had the pleasure of speaking with Marianna Cortese about her research in multiple sclerosis, including her interest in the microbiome.
In a Phase III clinical trial, a novel drug termed GV-971 has shown promise for improving cognition in people with mild-to-moderate Alzheimer’s disease.
The MS-STAT2 trial is underway, with researchers investigating simvastatin as a potential treatment option for individuals with secondary progressive multiple sclerosis.
Traumatic brain injury and circulating biomarkers: the CREACTIVE trial, an interview with Guido Bertolini
In this interview, we spoke with Guido Bertolini about the first results from the CREACTIVE trial on circulating biomarkers in traumatic brain injury.
A Phase II clinical trial of ibudilast has revealed that the drug decreases progression of brain atrophy in patients with progressive multiple sclerosis.
Results from the Phase III TOLEDO study suggests that treatment of Parkinson’s with apomorphine increases periods of good motor control and reduces periods when Parkinson’s disease medications are ineffective.
Researchers have demonstrated encouraging results in the treatment of Alzheimer’s disease using the experimental drug BAN2401; this treatment significantly slowed clinical cognitive decline and lead to a size reduction in amyloid plaques.
Topline results from the Phase II study with BAN2401, an anti-amyloid beta antibody, have been reported in patients with early Alzheimer’s disease.
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy, Parkinson’s disease and acute stroke.